Skip to main content
44°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
901.19
+7.05 (+0.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
April 17, 2024
Via
Benzinga
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
April 12, 2024
Via
Benzinga
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
April 11, 2024
The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated...
Via
Benzinga
Topics
Fraud
Exposures
Legal
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
April 11, 2024
Via
Benzinga
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
March 28, 2024
Via
Benzinga
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
April 11, 2024
Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise.
Via
Investor's Business Daily
Should You Sell This Stock Following a Regulatory Roadblock?
April 05, 2024
It's not the first such obstacle this high-performing drugmaker has faced.
Via
The Motley Fool
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
April 01, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
March 26, 2024
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For March 20
March 20, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
March 15, 2024
Via
Benzinga
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
March 28, 2024
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
Via
The Motley Fool
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
March 26, 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.
Via
InvestorPlace
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
March 25, 2024
The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data...
Via
Benzinga
Exposures
Product Safety
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
March 22, 2024
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend.
Via
InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
March 13, 2024
These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March.
Via
InvestorPlace
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
March 01, 2024
Via
Benzinga
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
February 27, 2024
Via
Benzinga
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
March 13, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
March 09, 2024
Good news could be in store for all three of these drugmakers.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
March 08, 2024
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in March
March 08, 2024
These stocks are worth buying in most months of the year.
Via
The Motley Fool
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
February 26, 2024
Via
Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.